Full Committee:Examining the Actions of Drug Companies in Raising Prescription Drug Prices
The purpose of the hearing is to determine why drug companies are increasing prices so dramatically, how drug companies are using the proceeds, and what steps can be taken to reduce prescription drug prices.
The Committee is investigating the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on federal and state budgets and on American families.
For years, drug companies have been aggressively increasing prices on existing drugs and setting higher launch prices for new drugs while recording windfall profits.
Approximately 94% of widely-used brand-name drugs on the market between 2005 and 2017 more than doubled in price during that time, and the average price increase in 2017 was 8.4%—four times the rate of inflation—according to an analysis conducted by AARP.
A recent Associated Press analysis found that more than 4,400 brand-name drugs increased in price in the first seven months of 2018 alone, compared to 46 price decreases.
Dr. Gerard Anderson
Professor of Health Policy and Management, Johns Hopkins University
Dr. Catherine Alicia Georges
National Volunteer President, AARP
Dr. Aaron Kesselheim
Associate Prof. of Medicine, Harvard Medical School
Mr. Avik S. A. Roy
President, The Foundation for Research on Equal Opportunity
Ms. Antroinette Worsham
Mother of Two Insulin-Dependent Daughters